MSS/ MMRp

我们是谁

  • 12 月 18, 2023
    Immunotherapy for Third Line Metastatic Colorectal Cancer
  • 11 月 13, 2023
    Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
  • 10 月 31, 2023
    表达高亲和性 KRASG12V 突变特异性 T 细胞受体的自体 CD8+ 和 CD4+ 转基因 T 细胞（FH-A11KRASG12V-TCR）用于治疗 KRAS G12V 突变的转移性胰腺癌、结直肠癌和非小细胞肺癌患者
  • 10 月 31, 2023
    无病变证据 (NED) 的 IV 期结直肠癌患者的 Durvalumab 加瑞戈非尼辅助治疗与未治疗对照组对比：VIVA 试验
  • 10 月 31, 2023
    Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
  • 10 月 17, 2023
    Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer
  • 10 月 17, 2023
    Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
  • 10 月 17, 2023
    Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
  • 8 月 31, 2023
    A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
  • 8 月 31, 2023
    Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer